microRNA Sequencing Service

What Is microRNA Sequencing

microRNA (miRNA) is a class of endogenous small non-coding RNA in eukaryotes, with a length of approximately 17 to 25 base pairs. Since the discovery of miRNA in 1993, advancements and discoveries in the field of small RNAs have revolutionized the understanding of gene regulation in the scientific community. From embryonic development to cell apoptosis and even tumor growth, miRNA plays a crucial role in a range of physiological and pathological processes. Various miRNAs associated with genetics, metabolism, infectious diseases, and tumors provide scientists with new perspectives for pathological research and may serve as reliable biomarkers for diseases. Scientists are actively exploring interventions and therapeutic treatments for diseases by manipulating miRNA functions and developing novel in vivo delivery methods. Furthermore, miRNA has been discovered to mediate cross-species evolution and adaptation, and there is still much more to explore regarding miRNA.

miRNA-seq is a high-throughput sequencing method developed to detect the expression of miRNAs. Drosha and Dicer, which are involved in miRNA processing, belong to the RNase III family of nucleases. Therefore, miRNAs have a 5' -PO4 group and a 3' -OH group, which can be directly used for ligation reactions. Additionally, miRNAs are characterized by their lengths of 18-30 nucleotides. Thus, by directly ligating total RNA and recovering the inserted fragments with lengths ranging from 18 to 30 nucleotides, miRNAs can be enriched, libraries can be constructed, and the expression of miRNAs can be analyzed.

Our miRNA Sequencing Service

CD Genomics applies high-throughput sequencing technology to sequence microRNA libraries. This technology allows for the acquisition of millions of microRNA sequences in a single run, enabling rapid identification of known and unknown microRNAs and their expression differences in different species, tissues, developmental stages, and disease states. Moreover, the next-generation sequencing technology has significant applications in the detection of microRNA complementary strands, microRNA editing, microRNA isoform detection, novel microRNA prediction, and microRNA target gene analysis. It provides a powerful tool for studying the role of microRNAs in cellular processes and their biological impacts.

CD Genomics microRNA Sequencing Services include quantification of customer-provided total RNA or microRNA samples, followed by microRNA library construction, cluster generation, and sequencing. CD Genomics's microRNA sequencing service offers comprehensive and integrated services from sample extraction to data analysis. The service includes sample extraction quality control, library preparation, sequencing, bioinformatics analysis, and data reporting.

Characteristics of miRNA Sequencing Technology

High Sensitivity: Theoretically capable of detecting a single copy of microRNA in a single cell.

High Precision: Capable of detecting single-base differences in microRNA.

Unaffected by prior information interference, capable of identifying known microRNAs and discovering new ones.

Preserves directional information for strand-specific expression analysis.

Utilizes barcodes to economically analyze multiple samples in a single run.

Technological Applications

Standalone Use: Studying the expression of miRNAs during biological processes.

Standalone Use: Researching miRNA biomarkers in biological fluids such as serum, plasma, and exosomes.

Combined Use with mRNA-seq: Constructing miRNA-mRNA regulatory networks during biological processes.

Combined Use with circRNA-seq: Constructing miRNA-circRNA regulatory networks.

Multi-omics Integration: Building circRNA-miRNA-mRNA regulatory networks.

Service Advantages

Highest sensitivity and lowest bias.

Utilizes UMI (Unique Molecular Identifier) digital tags to correct false-positive duplicates introduced by PCR and sequencing.

Strong bioinformatics analysis team providing comprehensive analysis results.

miRNA Sequencing Service Workflow

miRNA Sequencing Service Workflow

Service Specification

microRNA Sequencing Service Sample requirements and preparation
  • Sample type: Total RNA without degradation or DNA contamination
  • Starting amount of total RNA ≥ 5 µg
  • Sample concentration ≥ 200 ng/µl
  • Sample purity: OD260/280 = 1.8~2.2
  • All RNA samples are validated for purity and quantity
microRNA Sequencing Service Sequencing
  • Libraries of miRNA (15-30nt), small RNA (30-200nt), or custom size range
  • Illumina HiSeq SE50
  • ≥ 10 M reads
  • More than 90% of bases with a ≥Q30 quality score
microRNA Sequencing Service Bioinformatics Analysis We provide customized bioinformatics analysis including:
  • Raw data quality control and length filter
  • Reference-based mapping
  • Small RNA classification and quantification
  • Target gene prediction and annotation
  • Novel small RNA prediction
  • Target gene analysis of differentially expressed small RNA (GO enrichment and KEGG enrichment)

miRNA biomarkers for predicting overall survival outcomes for head and neck squamous cell carcinoma

Journal: Genomics

Impact factor: 6.205

Published: 2020


Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor of the upper digestive tract. Alterations in the function of miRNA can promote cancer development through various mechanisms. This study utilized RNA sequencing (RNA-seq) and miRNA sequencing data from the TCGA database to demonstrate the dysregulated miRNA microenvironment and provide valuable biomarkers for miRNA therapy. In the training set, seven miRNAs were identified as independent prognostic factors for HNSCC patients. These miRNAs collectively targeted 60 genes, among which nine target genes (CDCA4, CXCL14, FLNC, KLF7, NBEAL2, P4HA1, PFKM, PFN2, and SEPPINE1) were associated with overall survival (OS) of the patients. This study identified novel miRNA markers for predicting the prognosis of head and neck squamous cell carcinoma.

1. Data Acquisition

RNA-seq data and miRNA-seq data of HNSCC patients were downloaded from the TCGA database. The miRBase database contains known miRNA sequences and annotations, including information on the location and sequence of mature miRNAs. The Fasta format sequences of all mature miRNA sequences obtained from miRBase were used for miRNA annotation. RNA-seq data and miRNA-seq data were extracted from samples of 529 individuals (42 normal and 487 tumor) and 552 individuals (44 normal and 508 tumor), respectively. Clinical and pathological data collected concurrently included gender, age, staging, TNM classification, survival status, and survival days.

2. Establishment of miRNA-based Prognostic

Markers A total of 1,075 differentially expressed mRNAs (581 upregulated and 494 downregulated) and 313 differentially expressed miRNAs (203 upregulated and 110 downregulated) were obtained from the TCGA omics data analysis. Figures 1A-1B show the heatmaps and volcano plots of the top 20 upregulated/downregulated differentially expressed mRNAs, while Figures 1C-1D show the heatmaps and volcano plots of the top 20 upregulated/downregulated differentially expressed miRNAs. To select prognostic miRNAs, differential expression miRNAs were evaluated using univariate Cox analysis. In the univariate Cox analysis, 26 important miRNAs with significant changes were identified, among which seven differentially expressed miRNAs (hsa-miR-499a-5p, hsa-miR-99a-5p, hsa-miR-337-3p, hsa-miR-4746-5p, hsa-miR-432-5p, hsa-miR-142-3p, hsa-miR-137-3p) were identified as independent prognostic factors for HNSCC patients. Therefore, the formula for the model in this study is: Risk Score = (0.238 × hsa-miR-337-3p) + (0.246 × hsa-miR-99a-5p) - (0.232 × hsa-miR-4746-5p) - (0.233 × hsa-miR-432-5p) - (0.261 × hsa-miR-142-3p). Additionally, the risk scores for each patient in the study cohort were calculated. Then, the median risk score was used as the threshold value to divide patients into high-risk and low-risk groups in the training set, test set, and all patients.

microRNA Sequencing ServiceFig. 1. The volcano plot and heatmap of top 20 upregulated/downregulated differently expressed genes or miRNAs. A-B: mRNA; C-D: miRNAs.

3. Survival Outcomes and Multivariate Analysis

In this study, the expression of seven miRNAs in patient survival was analyzed using KM survival curves. It was found that hsa-miR-499a-5p, hsa-miR-99a-5p, hsa-miR-337-3p, hsa-miR-4746-5p, hsa-miR-432-5p, hsa-miR-142-3p, and hsa-miR-137-3p significantly influenced the overall survival (OS) outcomes (Figures 2A-G). Additionally, KM survival curves for the two datasets were used to assess the predictive value of the seven miRNAs. In both the training set and the test set, patients in the high-risk group had lower survival rates than those in the low-risk group. ROC curve analysis was conducted to determine if the expression patterns of the survival-associated miRNAs could provide early prediction of HNSCC occurrence. The results showed an AUC of 0.716 for the training set and an AUC of 0.654 for the test set, indicating moderate sensitivity and specificity of the prognostic model. The risk survival status plot demonstrated that as the patient's risk score increased, the mortality rate also increased (Figure 3). To establish a prognostic model based on the seven miRNAs, univariate and multivariate Cox analyses were performed to identify risk factors. The results revealed that based on the seven miRNA features, gender and N stage were independent prognostic factors for OS (Figure 4).

microRNA Sequencing ServiceFig. 2. Overall survival analysis of 7 miRNA, the training set and testing set. A-G: miRNAs; H: Training set; I: Testing set.

microRNA Sequencing ServiceFig. 3. The results of ROC curves and patient's risk survival status plot in training set and testing set. A: ROC in training set; B: ROC in testing set; C: Survival status in training set; D: Survival status in testing set.

microRNA Sequencing ServiceFig. 4. Univariate and multivariate COX analysis to identify the risk factors. A: Univariate; B: Multivariate.

4. miRNA Target Gene Analysis

The prediction of target genes for these seven miRNAs resulted in 60 target genes obtained from online databases. The potential connections between miRNAs and target genes were explored using Cytoscape. As shown in Figure 5, hsa-miR-137-3p was the largest node in the network, while hsa-miR-99a-5p and hsa-miR-4746-5p did not have matching target genes (red nodes represent upregulated, green nodes represent downregulated). To evaluate the biological functions of these target genes, GO enrichment and KEGG pathway analyses were conducted. GO analysis revealed enrichment of target genes in biological processes (BP) such as negative regulation of cellular processes, tissue development, and response to inhibitory factors. Molecular functions (MF) were enriched in extracellular matrix structural constituent, growth factor binding, actin binding, and protein tyrosine/serine/threonine phosphatase activity. Cellular components (CC) were primarily enriched in platelet alpha granule, condensed chromosome kinetochore, extracellular matrix, and other terms. KEGG pathway analysis indicated that these target genes were mainly enriched in the pentose phosphate pathway, galactose metabolism, and glycolysis/gluconeogenesis pathways (Figure 6).

microRNA Sequencing ServiceFig. 5. Cytoscape explored the potential link between microRNA and target genes.

microRNA Sequencing ServiceFig. 6. The results of GO analysis and KEGG analysis of target genes.

5. Relationship between miRNA

Target Genes and Survival Outcome Analyzing the impact of miRNA target gene expression on patient survival, it was found that the expression of nine genes: CDCA4, CXCL14, FLNC, KLF7, NBEAL2, P4HA1, PFKM, PFN2, and SEPPINE1, significantly influenced overall survival (OS) (Figures 7A-7I). The construction of a protein-protein interaction (PPI) network revealed two central key genes, PDGFRB and RAD51 (Figure 7J).

microRNA Sequencing ServiceFig. 7. Overall survival analysis of identified target genes and the protein-protein interaction (PPI) network. A-I: mRNA; J: PPI network.


This study, based on the TCGA dataset, identified an innovative miRNA feature and analyzed the prognosis of HNSCC. The research provides novel insights for the development of reliable tools for accurate prediction of cancer treatment outcomes. However, the limitations of this study include the lack of validation in clinical samples and relatively small sample size, which may limit the statistical power. The molecular markers identified should be validated in more independent studies and functional experiments.

For Research Use Only. Not for use in diagnostic procedures.
Quote Request
Contact CD Genomics
Terms & Conditions | Privacy Policy | Feedback   Copyright © CD Genomics. All rights reserved.